Jianyu W.

Establishing collaboration relationship using Insilico Medicine's proprietary AI Drug discovery software and hardware platforms and innovative medicine pipelines covering fibrosis diseases, oncology, immunology diseases, CNS diseases, Cardiovascular and metabolism disease and age-related diseases in the field of Pharmaceutical industry and beyond. Notable record: (1) Initiated, driving scientific review, research plan discussion and contract negotiation then closed AI-empowered drug discovery collaboration with Qilu Pharma in CVM disease field with total deal size 931 million HKD. This collaboration was announced on January 27th, 2026. (2) "End-to-End" closed a series of AI-empowered drug discovery collaborations across multiple projects in the fields of CNS and Autoimmune diseases with CMS. Insilico is expecting to receive R&D funding support of up to several tens of millions of HKD for each program. "End-to-End" means brought the lead, assign the internal resource with support from R&D leaders and my supervisors, driving scientific review and research plan discussion, contract negotiation and aligning both sides to ensure news release according to Insilico's plan. The collaboration was announced on February 10th, 2026.

Establish collaboration with clients globally using AI empowered Drug Discovery platforms and Innovation Drug Pipelines. Successful closed drug outlicensing deal as core BD team member, responsibility including Due Diligence, internal and external communication, etc. Successful achieved milestone as Alliance Manager role in clinical development, responsibility including internal and external communication, document managing, etc. Successful closed deal in AI empowered Drug Discovery SaaS. Notable record: (1) Leading clinical tech transfer to Exelixis after execution of XL309 (previous known as ISM3091, a potential best-in-class USP1 inhibitor) out-licensing deal. Aligned with Alliance Manager and project team from Exelixis and internal team to ensure tech transfer completed according to the plan. In December 2024, clinical development milestone had been achieved. (2) Leading Due Diligence and tech transfer plan negotiation with Menarini during MEN2312 (previously known as ISM5043, a potential best-in-class KAT6 inhibitor) out-licensing deal. This program is currently in clinical development stage. (3) Driving the whole Due Diligence, Q&A sessions, tech transfer plan negotiation with Menarini during MEN2501 (previously known as ISM9682, a potential best-in-class KIF18A inhibitor) out-licensing deal. This program has reached "first-patient-in dosed" milestone in February 2026.

Biology project leader in Oncology, Cancer immunotherapy and Immunology treatment area. Lead target investigation in Neuroscience field. Design and analyze in vitro and in vivo experiments and managing internal multi-functional team and external CROs. Participated one program which has nominated Preclinical candidate.

Using different gene mutation mouse model to explore disease related gene function. Built experience in animal research, neurobiology, molecular biology, etc. Main project is using adult HtrA2 knockout model to study HtrA2 function in adult brain.

1. Direct reprogramming of mouse and human somatic cells into neural stem cells and identification of induced neural stem cells in vitro and in vivo. 2. induced neural stem cells application in Parkinson's disease mouse models. 3. stem cells application in neurodegenerative diseases primate models.

PhD Student

Bachelor